Stock Analysis

Agenus Full Year 2022 Earnings: Revenues Beat Expectations, EPS In Line

Source: Shutterstock

Agenus (NASDAQ:AGEN) Full Year 2022 Results

Key Financial Results

  • Revenue: US$98.0m (down 67% from FY 2021).
  • Net loss: US$230.7m (loss widened by US$206.5m from FY 2021).
  • US$0.78 loss per share (further deteriorated from US$0.10 loss in FY 2021).
NasdaqCM:AGEN Earnings and Revenue Growth March 16th 2023

All figures shown in the chart above are for the trailing 12 month (TTM) period

Agenus Revenues Beat Expectations

Revenue exceeded analyst estimates by 19%. Earnings per share (EPS) was mostly in line with analyst estimates.

Looking ahead, revenue is forecast to grow 31% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are up 15% from a week ago.

Risk Analysis

You should always think about risks. Case in point, we've spotted 5 warning signs for Agenus you should be aware of, and 2 of them don't sit too well with us.

What are the risks and opportunities for Agenus?

Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally.

View Full Analysis


  • Revenue is forecast to grow 30.64% per year


  • Has less than 1 year of cash runway

  • Negative shareholders equity

  • Shareholders have been diluted in the past year

  • Volatile share price over the past 3 months

  • Currently unprofitable and not forecast to become profitable over the next 3 years

View all Risks and Rewards

Share Price

Market Cap

1Y Return

View Company Report